219 related articles for article (PubMed ID: 26518752)
1. Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth.
Zhao Y; Tu MJ; Yu YF; Wang WP; Chen QX; Qiu JX; Yu AX; Yu AM
Biochem Pharmacol; 2015 Dec; 98(4):602-13. PubMed ID: 26518752
[TBL] [Abstract][Full Text] [Related]
2. Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest.
Zhao Y; Tu MJ; Wang WP; Qiu JX; Yu AX; Yu AM
Sci Rep; 2016 May; 6():26611. PubMed ID: 27216562
[TBL] [Abstract][Full Text] [Related]
3. Bioengineering Novel Chimeric microRNA-34a for Prodrug Cancer Therapy: High-Yield Expression and Purification, and Structural and Functional Characterization.
Wang WP; Ho PY; Chen QX; Addepalli B; Limbach PA; Li MM; Wu WJ; Jilek JL; Qiu JX; Zhang HJ; Li T; Wun T; White RD; Lam KS; Yu AM
J Pharmacol Exp Ther; 2015 Aug; 354(2):131-41. PubMed ID: 26022002
[TBL] [Abstract][Full Text] [Related]
4. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
5. The Optimal Outcome of Suppressing Ewing Sarcoma Growth
Li DF; Yuan Y; Tu MJ; Hu X; Li YZ; Yi WR; Li PC; Zhao Y; Cheng Z; Yu AM; Jian C; Yu AX
Front Oncol; 2020; 10():222. PubMed ID: 32161722
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA SNHG7 Promotes the Tumor Growth and Epithelial-to-Mesenchymal Transition via Regulation of miR-34a Signals in Osteosarcoma.
Deng Y; Zhao F; Zhang Z; Sun F; Wang M
Cancer Biother Radiopharm; 2018 Nov; 33(9):365-372. PubMed ID: 29989838
[TBL] [Abstract][Full Text] [Related]
7. A genetically engineered microRNA-34a prodrug demonstrates anti-tumor activity in a canine model of osteosarcoma.
Alegre F; Ormonde AR; Snider KM; Woolard K; Yu AM; Wittenburg LA
PLoS One; 2018; 13(12):e0209941. PubMed ID: 30596759
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
9. The potential combinational effect of miR-34a with celecoxib in osteosarcoma.
Chen X; Peng D; Shen Y; Liu B; Zhou H; Tao H; Huang J
Anticancer Drugs; 2017 Sep; 28(8):888-897. PubMed ID: 28650862
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
Wang D; Bao H
Cancer Chemother Pharmacol; 2022 Jan; 89(1):31-40. PubMed ID: 34655298
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Jian C; Tu MJ; Ho PY; Duan Z; Zhang Q; Qiu JX; DeVere White RW; Wun T; Lara PN; Lam KS; Yu AX; Yu AM
Oncotarget; 2017 May; 8(19):30742-30755. PubMed ID: 28415566
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.
Wen J; Zhao YK; Liu Y; Zhao JF
Tumour Biol; 2017 Jun; 39(6):1010428317705761. PubMed ID: 28635396
[TBL] [Abstract][Full Text] [Related]
13. lncRNA C2dat1 Promotes Cell Proliferation, Migration, and Invasion by Targeting miR-34a-5p in Osteosarcoma Cells.
Jia D; Niu Y; Li D; Liu Z
Oncol Res; 2018 Jun; 26(5):753-764. PubMed ID: 28810936
[TBL] [Abstract][Full Text] [Related]
14. A novel small-molecule antagonist enhances the sensitivity of osteosarcoma to cabozantinib in vitro and in vivo by targeting DNMT-1 correlated with disease severity in human patients.
Wang JH; Zeng Z; Sun J; Chen Y; Gao X
Pharmacol Res; 2021 Nov; 173():105869. PubMed ID: 34481973
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone I restrains osteosarcoma progression by regulating circ_0000376/miR-432-5p/BCL2 axis.
Ye B; Qiao K; Zhao Q; Jiang Z; Hu N; Wang F
Mol Cell Biochem; 2022 Jan; 477(1):1-13. PubMed ID: 34532813
[TBL] [Abstract][Full Text] [Related]
17. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.
Gu Z; Zhou Y; Cao C; Wang X; Wu L; Ye Z
Biomed Pharmacother; 2020 Sep; 129():110363. PubMed ID: 32563982
[TBL] [Abstract][Full Text] [Related]
18. Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.
Yao C; Wu S; Li D; Ding H; Wang Z; Yang Y; Yan S; Gu Z
Mol Oncol; 2012 Aug; 6(4):392-404. PubMed ID: 22583777
[TBL] [Abstract][Full Text] [Related]
19. Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.
Qiu R; Ma G; Li X; Shi Q; Li X; Zhou X; Tang Y; Xie Z; Liao S; Qin Y; Wang R; Ye Y; Luo J; Zhang J
J Cell Biochem; 2019 Jun; 120(6):10697-10706. PubMed ID: 30652346
[TBL] [Abstract][Full Text] [Related]
20. Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy.
Yao C; Liu J; Wu X; Tai Z; Gao Y; Zhu Q; Li J; Zhang L; Hu C; Gu F; Gao J; Gao S
J Control Release; 2016 Jun; 232():203-14. PubMed ID: 27126903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
